Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinfo ...
A new study uncovers how widely used weight loss drugs like Ozempic impact various health conditions while posing notable ...
Nearly 70% of adults in Indiana are classified as overweight or obese, contributing to a broader health crisis in the United ...
Health-care companies rose after more promising data for the best-selling Glucagon-like Peptide inhibitor drugs. Shares of Novo Nordisk and Eli Lilly, the two leading producers of GLP-1 drugs, rallied ...
Glucagon-like peptide-1 receptor agonist use corresponded with risk reductions for dozens of diseases and adverse health ...
The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...
Computational research conducted by scientists from Washington University in St. Louis shows that GLP-1 agonists can have ...
A study by the Department of Veterans Affairs says that drugs like Ozempic can do plenty more than just help with weight loss ...
We recently compiled a list of the 9 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where ...
Fierce Healthcare is tracking workforce changes across healthcare in 2025. Stick with this tracker for the latest updates, ...
A new study found that GLP-1 medications like Ozempic can lower your risk for 42 conditions, including dementia. Here's what ...
A safety committee will review all evidence from trials and studies to shed more light on the potential risk of NAION.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback